Two-year clinical outcome after successful implantation of drug-eluting and bare metal stents in diabetic patients: Results from a real-world single center registry

Chinese Medical Journal

Volumn 122, Issue 6, 2009, Pages 612-616

  Dou, Ke Fei ^a   Xu, Bo ^a   Yang, Yue Jin ^a   Chen, Ji Lin ^a   Qiao, Shu Bin ^a   Li, Jian Jun ^a   Qin, Xue Wen ^a   Liu, Hai Bo ^a   Wu, Yong Jian ^a   Chen, Jue ^a   Yao, Min ^a   You, Shi Jie ^a   Yuan, Jin Qing ^a   Dai, Jun ^a   Gao, Run Lin ^a  

^a FUWAI HOSPITAL   (China)

Author keywords

Bare metal stent; Clinical outcome; Diabetes; Drug eluting stent

Indexed keywords

PACLITAXEL; RAPAMYCIN;

ADULT; ARTICLE; BARE METAL STENT; CONFIDENCE INTERVAL; CONTROLLED STUDY; CORONARY ARTERY RECANALIZATION; DEATH; DIABETES MELLITUS; DIABETIC PATIENT; DRUG ELUTING STENT; FEMALE; HAZARD RATIO; HEART INFARCTION; HUMAN; INTERVENTIONAL CARDIOVASCULAR PROCEDURE; MAJOR CLINICAL STUDY; MALE; OUTCOME ASSESSMENT; PERCUTANEOUS CORONARY INTERVENTION; PROPORTIONAL HAZARDS MODEL; REGISTER; RISK ASSESSMENT; SCORING SYSTEM; STENT THROMBOSIS; THROMBUS; AGED; CORONARY ARTERY DISEASE; METHODOLOGY; MIDDLE AGED; PROSPECTIVE STUDY; TRANSLUMINAL CORONARY ANGIOPLASTY; TREATMENT OUTCOME;

AGED; ANGIOPLASTY, TRANSLUMINAL, PERCUTANEOUS CORONARY; CORONARY DISEASE; DIABETES COMPLICATIONS; DRUG-ELUTING STENTS; FEMALE; HUMANS; MALE; MIDDLE AGED; PROSPECTIVE STUDIES; TREATMENT OUTCOME;

EID: 67649816894     PISSN: 03666999     EISSN: None     Source Type: Journal    
DOI: 10.3760/cma.j.issn.0366-6999.2009.06.004     Document Type: Article

References (28)

1. Wilson SR, Vakili BA, Sherman W, Sanborn TA, Brown DL. Effect of diabetes on long-term mortality following contemporary percutaneous coronary intervention: analysis of 4284 cases. Diabetes Care 2004; 27: 1137-1142.
2. Abizaid A, Kornowski R, Mintz GS, Hong MK, Abizaid AS, Mehran R, et al. The influence of diabetes mellitus on acute and late clinical outcomes following coronary stent implantation. J Am Coll Cardiol 1998; 32: 584-589.
3. Elezi S, Kastrati A, Pache J, Wehinger A, Hadamitzky M, Dirschinger J, et al. Diabetes mellitus and the clinical and angiographic outcome after coronary stent placement. J Am Coll Cardiol 1998; 32: 1866-1873.
4. Schofer J, Schluter M, Rau T, Hammer F, Haag N, Mathey DG.. Influence of treatment modality on angiographic outcome after coronary stenting in diabetic patients:a controlled study. J Am Coll Cardiol 2000; 35: 1554-1559.
5. Van Belle E, Perie M, Braune D, Chmait A, Meutice T, Abolmaali K, et al. Effects of coronary stenting on vessel patency and long-term clinical outcome after percutaneous coronary revascularization in diabetic patients. J Am Coll Cardiol 2002; 40: 410-417.
6. Babapulle MN, Joseph L, Belisle P, Brophy JM, Eisenberg MJ. A hierarchical Bayesian meta-analysis of randomized clinical trials of drug-eluting stents. Lancet 2004; 364: 583-591.
7. Stettler C, Wandel S, Allemann S, Kastrati A, Morice MC, Schomig A, et al. Outcomes associated with drug-eluting stents and bare metal stents: a collaborative net work meta-analysis. Lancet 2007; 370: 937-948.
8. Shuchman MS. Tradig restenosis for thrombosis? New questions about durg-eluting stents. N Engl J Med 2006; 335: 1949-1952.
9. Moreno R, Fernández C, Hernández R, Alfonso F, Angiolillo DJ, Sabate M, et al. Drug-eluting stent thrombosis: results from a pooled analysis including 10 randomized studies. J Am Coll Cardiol 2005; 45: 954-959.
10. Bavry AA, Kumbhani DJ, Helton TJ, Bhatt DL. What is the risk of stent thrombosis associated with the use of paclitaxel-eluting stents for prcuatneous coronary interventions. J Am Coll Cardiol 2005; 45: 941-946.
11. Cutlip DE, Windecker S, Mehran R, Boam A, Cohen DJ, van Es GA, et al. On behalf of the Academic Research Consortium. Clinical end points in coronary stent trials: a case for standardized definitions. Circulation 2007; 115: 2344-2351.
12. Elezi S, Kastrati A, Pache J, Wehinger A, Hadamitzky M, Dirschinger J, et al. Diabetes mellitus and the clinical and angiographic outcome after coronary stent placement. J Am Coll Cardiol 1998; 32: 1866-1873.
13. Marzocchi A, Saia F, Piovaccari G, Manari A, Aurier E, Benassi A, et al. Long-term safety and efficacy of drug-eluting stents: two-year results of the REAL Multicenter Registry. Circulation 2007; 115: 3181-3188.
14. Williams DO, Abbott JD, Kip KE. Outcomes of 6960 patients undergoing percutaneous coronary intervention in the era of drug-eluting stents: report of the DEScover Registry. Circulation 2006; 114: 2154-2162.
15. Ortolani P, Balducelli M, Marzaroli P, Piovaccari G, Menozzi A, Guiducci V, et al. Two-year clinical outcomes with drug-eluting stents for diabetic patient with de novo coronary lesions: results from a real-world multicenter registry. Circulation 2008; 119: 923-930.
16. Garg P, Normand SL, Silbaugh TS, Wolf RE, Zelevinsky K, Lovett A, et al. Drug-eluting of bare-metal stenting in patients with diabetes mellitus: results from the Massachusetts data analysis center registry. Circulation 2008; 118: 2277-2285.
17. Spaulding C, Daemen J, Boersma E, Cutlip DE, Serruys PW. A pooled analysis of data comparing sirolimus-eluting stents with bare-metal stents. N Engl J Med 2007; 356: 989-997.
18. Stettler C, Allemann S, Wandel S, Kastrati A, Morice MC, Schomig A, et al. Drug eluting and bare metal stents in people with and without diabetes: collaborative network meta-analysis. BMJ 2008; 337: a1331.
19. Boyden TF, Nallamothu BK, Moscucci M, Chan PS, Grossman PM, Tsai TT, et al. Meta-analysis of randomized trials of drug-eluting stents versus bare metal stents in patients with diabetes mellitus. Am J Cardiol 2007; 99: 1399-1402.
20. Daemen J, Garcia HM, Kukreja N, Imani F, De Jaegere PP, Sianos G, et al. The long-term value of sirolimus- and paclitaxel-eluting stents over bare metal stents in patients with diabetes mellitus. Eur Heart J 2007; 28: 26-32.
21. Stone GW, Moses JW, Ellis SG, Schofer J, Dawkings KD, Morice MC, et al. Safety and efficacy of sirolimus- and paclitaxel-eluting coronary stents. N Engl J Med 2007; 356: 998-1008.
22. Nebeker JR, Virmani R, Bennett CL, Hoffman JM, Samore MH, Alvarez J, et al. Hypersensitivity cases associated with drug-eluting coronary stents:a review of available cases from the Research on Advrse Durg Events and Reports (RADAR) project. J Am Coll Cardiol 2006; 47: 175-181.
23. Guagliumi G, Farb A, Musumci G, Valsecchi O, Tespili M, Motta T, et al. Sirolimus-eluting stent implanted in human coronary artery for 16 months: pathological findings. Circulation 2003; 107: 1340-1341.
24. Fere F, Costa JR, Abizaid A. Very late thrombosis after durg-eluting stents. Catheter Cardiovasc Interv 2006; 68: 83-88.
25. Sabate M, Jimenez-Quevedo P, Angiolillo DJ, Gomez- Hospital JA, Alfonso F, Hernandez-Antolin R, et al. Randomized comparison of sirolimus-eluting stent versus standard stent for percutaneous coronary revascularization in diabetic patients: the Diabetes and Sirolimus-Eluting Stent (DIABETES) Trial. Circulation 2005; 112: 2175-2183.
26. Baumgart D, Klauss V, Baer F, Hartmann F, Drexler H, Motz W, et al. One-year results of the SCORPIUS study: a German multicenter investigation on the effectiveness of sirolimus-eluting stents in diabetic patients. J Am Coll Cardiol 2007; 50: 1627-1634.
27. Moussa I, Leon MB, Baim DS, O'Neill WW, Popma JJ, Buchbinder M, et al. Impact of sirolimus-eluting stents on outcome in diabetic patients: a SIRIUS (SIRolimUS-coated Bx Velocity balloon-expandable stent in the treatment of patients with de novo coronary artery lesions) substudy. Circulation 2004; 109: 2273-2278.
28. Dibra A, Kastrati A, Mehilli J, Pache J, Schuhlen H, von Beckerath N, et al. Paclitaxel-eluting or sirolimus-eluting stents to prevent restenosis in diabetic patients. N Engl J Med 2005; 353: 663-670.